Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases

Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases

<b>Background:</b> For several decades, PD-1 has been a target in malignant melanoma (MM). PD-1 inhibitors (nivolumab, pembrolizumab) and anti-CTLA-4 (CD152) (ipilimumab) have revolutionized cancer therapy. PD-1 and CTLA-4 inhibition leads to prolonged lymphocyte effects, which explains...

Full description

Bibliographic Details
Main Authors: Jean-Matthieu L’Orphelin, Emilie Varey, Amir Khammari, Brigitte Dreno, Anne Dompmartin
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
melanoma
adverse events
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/13/19/4928

Similar Items

Similar Items